Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach
在慢性淋巴细胞白血病(CLL)患者中,将乌布拉利西布和乌布利妥昔单抗(U2)加入伊布替尼治疗方案中:一项基于微小残留病灶(MRD)的II期研究
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-22-0964
Roeker, Lindsey E; Feldman, Tatyana A; Soumerai, Jacob D; Falco, Victoria; Panton, Gail; Dorsey, Colleen; Zelenetz, Andrew D; Falchi, Lorenzo; Park, Jae H; Straus, David J; Pena Velasquez, Camila; Lebowitz, Sonia; Fox, Yehudit; Battiato, Kristen; Laudati, Carissa; Thompson, Meghan C; McCarthy, Elizabeth; Kdiry, Sabrina; Martignetti, Rosalba; Turpuseema, Teja; Purdom, Michelle; Paskalis, Dana; Miskin, Hari P; Sportelli, Peter; Leslie, Lori A; Mato, Anthony R